<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Revenue Forecast on FinanClub</title>
    <link>https://finan.club/tags/revenue-forecast/</link>
    <description>Recent content in Revenue Forecast on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sun, 27 Aug 2023 09:10:39 +0000</lastBuildDate><atom:link href="https://finan.club/tags/revenue-forecast/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>GPS</title>
      <link>https://finan.club/us/gps/</link>
      <pubDate>Sun, 27 Aug 2023 09:10:39 +0000</pubDate>
      
      <guid>https://finan.club/us/gps/</guid>
      <description>score:-11
Chances: Gap surpasses Q2 earnings estimates despite a weak forecast. Positive focus on profit beat and strong Q2 earnings performance. Gap reports profit beat and slight revenue miss, comp. sales dip. Analysts highlight potential for Gap&amp;rsquo;s growth after positive Q2 performance. Gap&amp;rsquo;s strategic partnerships and limited-edition collections contribute to opportunities.</description>
    </item>
    
    <item>
      <title> GILD</title>
      <link>https://finan.club/us/gild/</link>
      <pubDate>Tue, 08 Aug 2023 07:17:02 +0000</pubDate>
      
      <guid>https://finan.club/us/gild/</guid>
      <description>score:724
Chances: Gilead Sciences expects a third of sales to come from its cancer treatments by 2030, driving optimism and stock price movement. Gilead Sciences is focused on developing therapies for life-threatening infectious diseases and expanding its portfolio to include pulmonary, cardiovascular diseases, and cancer treatments.</description>
    </item>
    
  </channel>
</rss>
